About
Copy Link
Titles
Hospital Resident
Biography
Undergraduate: Wichita State University, BSN
Interests: Oncology
Last Updated on August 16, 2021.
Education & Training
- MD
- University of Pittsburgh School of Medicine (2021)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Oluwaseun Ayoade's published research.
Publications Timeline
A big-picture view of Oluwaseun Ayoade's research output by year.
Daniel Boffa, MD
Maureen Canavan, PhD, MPH
Giorgio Caturegli, MD
Benjamin Resio, MD
Emily June Zolfaghari, MD, MS
Gavitt Woodard, MD
17Publications
30Citations
Publications
2026
Updated Review: Using the National Cancer Database for Outcomes-Based Research.
Ayoade O, Caturegli G, Palis B, McCabe R, Weigel R, Canavan M, Boughey J, Boffa D. Updated Review: Using the National Cancer Database for Outcomes-Based Research. Journal Of The American College Of Surgeons 2026 PMID: 41848188, DOI: 10.1097/xcs.0000000000001924.Peer-Reviewed Original ResearchAltmetricConceptsNational Cancer DatabaseFollow-upNon-small cell lung cancerAmerican CollegeCell lung cancerNarrative reviewCancer Reporting SystemCancer-accredited hospitalsPD-L1Tumor gradeTumor sizeCancer DatabaseContinuous tumor sizeLung cancerSmoking statusOutcomes-based researchOncology practiceSurvival dataMedicaid expansion statusOutcome studiesFollow-up limitCancerTreatment reportsPolicy changesPolicy-relevant dataUse of Complementary and Alternative Medicine in the Management of Breast Cancer
Ayoade O, Caturegli G, Canavan M, Resio B, Berger E, Boffa D. Use of Complementary and Alternative Medicine in the Management of Breast Cancer. JAMA Network Open 2026, 9: e260337. PMID: 41770560, PMCID: PMC12954545, DOI: 10.1001/jamanetworkopen.2026.0337.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsCohort studyManagement of breast cancerBreast cancerCohort study of dataMedical management of breast cancerTreated with CAMCox proportional hazards modelsMedical managementYear of diagnosisFemale patientsCombination of CAMProportional hazards modelTraditional therapiesAlternative medicineStudy of dataMain OutcomesEndocrine therapyNo treatmentCharlson Comorbidity IndexInsurance typeNonmedical personnelPrimary outcomeFacility typeSurvival timeHazards model
2025
P1.07.31 Adjuvant Immunotherapy for Clinically Node-Negative Non-Small Cell Lung Cancer
Caturegli G, Canavan M, Ayoade O, Resio B, Boffa D. P1.07.31 Adjuvant Immunotherapy for Clinically Node-Negative Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2025, 20: s148-s149. DOI: 10.1016/j.jtho.2025.09.274.Peer-Reviewed Original ResearchP2.08.07 Lymph Node Yield and Survival Among Lung Cancer Patients Treated With Neoadjuvant Systemic Therapy
Caturegli G, Canavan M, Ayoade O, Resio B, Boffa D. P2.08.07 Lymph Node Yield and Survival Among Lung Cancer Patients Treated With Neoadjuvant Systemic Therapy. Journal Of Thoracic Oncology 2025, 20: s343. DOI: 10.1016/j.jtho.2025.09.643.Peer-Reviewed Original ResearchReal-world perioperative outcomes of neoadjuvant chemoimmunotherapy in non–small cell lung cancer
Caturegli G, Kaminski M, Canavan M, Ayoade O, Resio B, Boffa D. Real-world perioperative outcomes of neoadjuvant chemoimmunotherapy in non–small cell lung cancer. JTCVS Open 2025, 28: 554-564. PMID: 41473080, PMCID: PMC12745116, DOI: 10.1016/j.xjon.2025.09.016.Peer-Reviewed Original ResearchAltmetricConceptsNon-small cell lung cancerPathological complete responseNational Cancer DatabaseNeoadjuvant chemoimmunotherapyCell lung cancerChemoimmunotherapy patientsNeoadjuvant chemoradiotherapyPerioperative outcomesStage I to III non-small cell lung cancerIII non-small cell lung cancerLung cancerTreated with neoadjuvant chemoimmunotherapyNon-small cell lung cancer recurrenceOutcome of immunotherapyPeri-operative outcomesMethods Adult patientsInduction chemoimmunotherapyComplete responseNeoadjuvant chemotherapyNodal downstagingPerioperative therapyCancer DatabasePneumonectomy rateChemoimmunotherapyAdult patientsErratum to ‘Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata’ [JTO Clinical and Research Reports Volume 6 Issue 4 (2025) 100798]
Ayoade O, Canavan M, Zolfaghari E, Caturegli G, Kim S, Boffa D. Erratum to ‘Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata’ [JTO Clinical and Research Reports Volume 6 Issue 4 (2025) 100798]. JTO Clinical And Research Reports 2025, 6: 100850. PMID: 41473839, PMCID: PMC12745935, DOI: 10.1016/j.jtocrr.2025.100850.Peer-Reviewed Original ResearchDefinitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer.
Caturegli G, Canavan M, Ayoade O, Woodard G, Boffa D, Resio B. Definitive radiation as a nonsurgical option after chemoimmunotherapy for stage III lung cancer. Journal Of Clinical Oncology 2025, 43: 8072-8072. DOI: 10.1200/jco.2025.43.16_suppl.8072.Peer-Reviewed Original ResearchConceptsStage III non-small cell lung cancerIII non-small cell lung cancerNon-small cell lung cancerThree-year overall survivalNonsurgical optionsDefinitive radiationLocal therapyOverall survivalClinical stage III non-small cell lung cancerLung cancerClinical stage III patientsStage III NSCLC patientsStage III lung cancerSquamous cell carcinoma patientsStage III lung adenocarcinomaIII NSCLC patientsInitiation of radiationNon-operative formsCharlson-Deyo scoreIII lung cancerNational Cancer DatabaseStage III patientsTreated with radiationCell carcinoma patientsKaplan-Meier methodSurvival of patients diagnosed with stage IV cancer in 2020 based on COVID-19 status.
Ayoade O, Canavan M, Caturegli G, Zolfaghari E, Resio B, Woodard G, Boffa D. Survival of patients diagnosed with stage IV cancer in 2020 based on COVID-19 status. Journal Of Clinical Oncology 2025, 43: e24041-e24041. DOI: 10.1200/jco.2025.43.16_suppl.e24041.Peer-Reviewed Original ResearchConceptsCancer patient survivalPatient survivalTumor behaviorCOVID-19 infectionCancer typesCharlson-Deyo scoreNational Cancer DatabaseSurvival of patientsKaplan Meier analysisCox proportional hazards modelsStage IV cancerAssociated with lower mortality riskProportional hazards modelCOVID-positive patientsMeier analysisCancer DatabaseLower mortality riskPositive patientsTreatment modalitiesDeyo scoreIV cancerImmune modulationImmunological consequencesCancer patientsYear mortalityRecent Survival Gains in Stage IV NSCLC by Sociodemographic Strata
Ayoade O, Canavan M, Zolfaghari E, Caturegli G, Kim S, Boffa D. Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata. JTO Clinical And Research Reports 2025, 6: 100798. PMID: 40212792, PMCID: PMC11985032, DOI: 10.1016/j.jtocrr.2025.100798.Peer-Reviewed Original ResearchCitationsAltmetricConceptsNon-small cell lung cancerStage IV non-small cell lung cancerIV non-small cell lung cancerStage IV NSCLC patientsIV NSCLC patientsCell lung cancerMedian survivalNSCLC patientsLung cancerNon-small cell lung cancer patientsNational Cancer DatabaseKaplan Meier methodTwo-year survivalStratified Cox analysisAdjusted mortality riskMeier methodCancer DatabaseCox analysisEra 1NSCLC treatmentSurvival gainChemotherapy administrationNon-Hispanic blacksPatientsHispanic patients
2024
Barriers to fitness: Disparities in preoperative exercise access for patients with lung cancer
Zolfaghari E, Ayoade O, Antonoff M. Barriers to fitness: Disparities in preoperative exercise access for patients with lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2024, 169: e39. PMID: 39674938, DOI: 10.1016/j.jtcvs.2024.11.023.Peer-Reviewed Original ResearchCitationsAltmetric
News
Copy Link
Get In Touch
Copy Link